series-c-plus
Stage
1
Investors
About
nChroma develops proprietary chromatin-targeting technologies to enable precise epigenetic modulation for therapeutic applications in diseases.
Explore nChroma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.